Sen. Mike Crapo (R-Idaho), ranking member of the Senate Finance Committee, said penny pricing under 340B warranted “serious scrutiny in the context of generic products.”
Two Senior GOP Senators Suggest 340B Linked to Generic Drug Shortages
Two Republican Senators on an influential committee suggested during a hearing on Tuesday that 340B discounts could contribute to certain [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.